Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.


Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.


You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

Lilly Q2 '21 Earnings Update

Here is a brief preview of this blast: Lilly hosted its Q2 ’21 earnings call and provided updates across its CV/Met portfolio, specifically for tirzepatide and Jardiance. Unsurprisingly, much of the call focused on donanemab for the treatment of Alzheimer’s disease following FDA’s June 2021 approval of Aduhelm (aducanamab) for the same treatment. Of note, Lilly disclosed it intends to host an in-person investor event in December 2021 to provide pipeline updates and initial guidance. Below, FENIX provides highlights and insights from the Lilly earnings call.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.